Navigation Links
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Date:9/4/2007

Trial Meets Primary and All Secondary Endpoints

San Carlos, Calif., Sept. 4 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, today announced positive top-line results from its second pivotal study of NGX-4010, the Company's dermal patch containing the TRPV1 agonist -- synthetic capsaicin -- in patients with postherpetic neuralgia (PHN). The study, a multi-center, double-blind, controlled Phase 3 trial, met its pre-specified primary endpoint: the reduction in pain from baseline to study weeks 2-8 (p=0.01). The study demonstrated a 32% reduction in pain from baseline from a single 60-minute application of NGX-4010 as compared to a 24% reduction in pain in the control group. Additionally, significant results were achieved for study weeks 2-12 (p<0.02), a secondary endpoint. All other secondary endpoints, including 30% and 50% responder analyses, were also met.

The study evaluated 416 patients enrolled at study sites in both the United States and Canada. Similar in design to the Company's previous, successfully completed C116 Phase 3 trial, the C117 trial evaluated the effect of a single, 60-minute treatment with NGX-4010 compared to a control patch containing a low concentration of NGX-4010's active ingredient. The treatment was administered by a study physician during an in-office procedure. After one hour, the patch was removed and the patient's response to treatment was evaluated daily using an 11-point numeric pain rating scale during the subsequent 12-week study period.

The initial safety analysis of the clinical trial results was consistent with the safety profile observed in previous Phase 3 stu
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets ... Chinese Medical X-ray Film Industry Report 2014" report ... Global And Chinese Medical X-Ray Film ... on the current state of the Global medical X-ray ... The report provides a basic overview of the ...
(Date:7/11/2014)...  Kindred Hospital Houston Northwest, with Wound Care ... its new outpatient wound healing center.  The wound ... chronic, hard to heal wounds. Chronic wounds include ... lower leg wounds related to blood flow issues, ... injury wounds which are complex and demonstrate delayed ...
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
(Date:7/13/2014)... Fuel additives are chemicals, which are ... fuel, kerosene, and so on, in order to enhance ... the corrosion effects caused by fuels and improving the ... fuel, provide economies of scale in the long run, ... cost of the fuel products. , The various fuel ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
Breaking Medicine News(10 mins):Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... EPIDEMIC ABROADMENLO PARK, Calif., May 7 Two-thirds of ... government funding to improve health in developing countries, while ... spending too much on global health, according to a ... towards U.S. global health and development assistance. Levels ...
... better than no treatment at all, study shows , , ... essential for reducing the risk of heart disease and ... matter of debate. , Now, two new analyses attempt ... attacks, all antihypertensive drugs work, with the exception of ...
... million adultsor one fourth of the people in the ... and this undiagnosed population accounts for an estimated $18 ... a study in a recent issue of Population ... Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... of Illinois at Chicago has received nearly $1 million ... to study the benefits of green healthy housing. , ... and Reinvestment Act of 2009. , UIC researchers will ... move from distressed, unhealthy public housing into green, affordable, ...
... Results in New Compounded Medication Program GLEN BURNIE, ... largest practice-to-home delivery veterinary pharmacy today announced the ... than 1,200 pet owners from across the U.S.Key ... about having convenient services and options that help ...
... Pharma GmbH received an Orphan Drug Designation (ODD) by ... the EMEA for inhaled PARI Tobramycin 100 delivered via ... the second ODD designation that PARI Pharma has received ... first ODD was granted for PARI,s inhaled cyclosporine delivered ...
Cached Medicine News:Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 2Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 3Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 4Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 5Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 6Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 2Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 3Health News:UIC receives $1M HUD grant to study green healthy housing 2Health News:VetCentric Releases Findings of Pet Owner Survey 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 3Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 4
... The Genesis II* Total Knee System ... Now, far more is possible with less ... options, while fully addressing both clinical and ... components meet these design goals, giving surgeons ...
Cruciate retaining, posterior stabilized and constrained components....
... The TC-PLUS Solution tricompartmental total knee prosthesis ... knee arthroplasty. State-of-the-art design and manufacturing technologies ... optimum biomechanical function as well as a ... tibial insert to keep wear to a ...
...
Medicine Products: